Modified Xiaoyaosan Combined with UDCA in Treatment of Refractory Jaundice (Liver-Qi Stagnation and Spleen Deficiency Type) in 31 Cases
|School||Hubei University of Chinese Medicine|
|Course||Traditional Chinese Medicine|
|Keywords||Refractory jaundice Stagnation and spleen deficiency Xiaoyaosan Ursofalk Integrative Medicine|
Objective: To observe the Bureau the party Xiaoyaosan United UDCA treatment of chronic hepatitis B and hepatitis B cirrhosis associated with refractory jaundice (liver depression and spleen), clinical efficacy, and from the two aspects of the clinical research and theory to explore Xiaoyaosan United UDCA treatment mechanism. Methods: The patients were 2010.02 to 2011.03 in Wuhan Chinese Medicine Hospital gastroenterology clinic patients, in line with the 2005 Chinese Medical Association Hepatology and Infectious Diseases, Chinese Medical Association credits will formulate chronic hepatitis B prevention and treatment guidelines diagnostic criteria. Cirrhosis caused by to select chronic hepatitis B and hepatitis B, TCM comply with of TCM Yin Huang stagnation and spleen deficiency patients, ALT restore basic normal liver function after the hepatoprotective, JiangMei, Tuihuang comprehensive treatment, but TBIL still higher (TBIL : 20μmol/L80μmol/L), repeated abnormal nearly six months, 62 cases were randomly divided into two groups. Treatment group, 31 cases, 31 cases of the control group. The two groups of age, gender, illness compared the difference was not statistically significant, comparable (P gt; 0.05). 2. Both groups were given UDCA therapy, higher liver transaminases plus five ester capsules of HBVDNA positive to anti-viral treatment routine anti-viral treatment, with ascites appropriate given furosemide and spironolactone line profit water treatment. Treatment group on the basis of the above treatment plus Bureau to treated Xiaoyaosan. The treatment lasted four weeks. During treatment, the two groups of patients are not taking other drugs, in addition to the drugs. 3. Observed adverse reactions, to make safety evaluation; each record before and after treatment, clinical symptoms, TBIL, ALT standard according clinics, making efficacy evaluation. Results: 1 total efficacy analysis: the treatment group after 4 weeks of treatment, the application of Integrative Medicine 31 cases, 11 cases markedly effective in 13 cases, invalid 7. Cases, the total effective rate was 77.42%; 31 cases of the control group, six cases were markedly 10 cases, 15 cases ineffective, the total effective rate was 51.61%. The two groups by statistical analysis, the total effective rate in the treatment group than the control group total efficiency (P lt; 0.05), indicating that the total effect of the treatment group than the control group. Total score of clinical symptoms: After treatment, the total score of clinical symptoms before treatment were significantly different (P lt; 0.01); comparing the total score of the treatment group and the control group of clinical symptoms after the treatment, the treatment group was significantly better than the control group (P lt ; 0.05). 3. Before and after treatment TBIL ALT changes in comparison: ① The treatment group TBIL than before treatment more significant difference (P lt; 0.01), the control group after treatment the TBIL than before treatment compared significant differences (P lt; 0.05); ALT than before treatment after treatment in the two groups when compared to the significant difference (P lt; 0.05); (2) the two groups after treatment compared the TBIL of the treatment group compared with the control group a significant difference (P lt; 0.05); However, ALT no significant difference (P gt; 0.05). To sum up, indicating that the two groups could significantly improve the patient's liver function, reduce TBIL, ALT, but the treatment group than the control group to reduce the patient's TBIL, while in the lower ALT, the two groups had similar efficacy. Conclusion: Through this clinical study show that the Bureau Xiaoyaosan subtraction joint UDCA treatment of chronic hepatitis B and hepatitis B cirrhosis associated with refractory jaundice (liver depression and spleen), the efficacy of the clinical symptoms better than the simple use of UDCA treatment of the disease; show that the two groups could significantly improve the patient's liver function, reduce TBIL, ALT, but the treatment group than the control group to reduce the patient's TBIL, while in the lower ALT, the two groups had similar efficacy. I believe that the combined UDCA Xiaoyaosan therapeutic effect following: (1) Ursofalk strong cholagogue quickly subsided jaundice to reduce intrahepatic cholestasis, and given to the patients to continue treatment. confidence. UDCA still protect the liver cell membrane, inhibition of hepatic apoptosis, regulating immunity, and the role of, can protect the liver cells and improve the immune system of elderly patients, can promote the recovery of the disease and reduce the various complications. ② Bureau Xiaoyaosan can only liver and spleen qi, heat and dampness jaundice, blood cooling blood, both dampness, stasis, heat of the evil, but also help blood being, in order to avoid Quxie gas hurt blood consumption, is virtual evil love, refractory lingering illness, from the root of the problem, to meet the \③. Modern research has shown that such treatment of jaundice, the Bureau Xiaoyaosan Ursofalk synergies.